Literature DB >> 12140675

Comparison of clinical types of Wilson's disease and glucose metabolism in extrapyramidal motor brain regions.

W Hermann1, H Barthel, S Hesse, F Grahmann, H-J Kühn, A Wagner, T Villmann.   

Abstract

In Wilson's disease a disturbed glucose metabolism especially in striatal and cerebellar areas has been reported. This is correlated with the severity of extrapyramidal motor symptoms (EPS). These findings are only based on a small number of patients. Up to now it is unknown whether EPS are caused by various patterns of disturbed basal ganglia glucose metabolism. We investigated 37 patients and 9 normal volunteers to characterize the disturbed glucose metabolism in Wilson's disease more precisely. The glucose metabolism was determined in 5 cerebellar and cerebral areas (putamen, caput nuclei caudati, cerebellum, midbrain and thalamic area) by using (18)F-Fluorodesoxyglucose-Positron-Emission-Tomography ( [(18)F]FDG-PET). The database was evaluated by a cluster analysis. Additionally, the severity extrapyramidal motor symptoms were judged by a clinical score system. Three characteristic patterns of glucose metabolism in basal ganglia were obtained. Two of them may be assigned to patients with neurological symptoms whereas the third cluster corresponds to most patients without EPS or normal volunteers. The clusters can be identified by characteristic consumption rates in this 5 brain areas. The severity of EPS can not clearly be assigned to one of the clusters with disturbed glucose metabolism. However, the most severe cases are characterized by the lowest consumption in the striatal area. When there is marked improvement of EPS impaired glucose consumption reveals a persistent brain lesion. Finally, the neurological symptoms in Wilson's disease are caused by (at least) two different patterns of disturbed glucose metabolism in basal ganglia and cerebellum. The severity of EPS seems to be determined by a disturbed consumption in the striatal area.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12140675     DOI: 10.1007/s00415-002-0756-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  [Wilson's disease and Westphal-Strümpell pseudosclerosis: conceptual history in German-speaking countries].

Authors:  P Boide; A Wagner; H Steinberg
Journal:  Nervenarzt       Date:  2011-10       Impact factor: 1.214

2.  [Classification of Wilson's disease based on neurophysiological parameters].

Authors:  W Hermann; P Günther; A Wagner; T Villmann
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

3.  Profound midbrain atrophy in patients with Wilson's disease and neurological symptoms?

Authors:  K Strecker; J P Schneider; H Barthel; W Hermann; F Wegner; A Wagner; J Schwarz; O Sabri; C Zimmer
Journal:  J Neurol       Date:  2006-04-10       Impact factor: 4.849

Review 4.  Wilson disease.

Authors:  Reinhard Kitzberger; Christian Madl; Peter Ferenci
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

5.  [Electrophysiological impairment profile of patients with Wilson's disease].

Authors:  W Hermann; T Villmann; A Wagner
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

6.  Fine motor skills disorders in the course of Wilson's disease.

Authors:  Peter Albrecht Günther; Hans-Juergen Kühn; Thomas Villmann; Wieland Hermann
Journal:  Ann Indian Acad Neurol       Date:  2009-01       Impact factor: 1.383

7.  FDG-PET findings in patients with galactosaemia.

Authors:  J G Dubroff; C Ficicioglu; S Segal; N A Wintering; A Alavi; A B Newberg
Journal:  J Inherit Metab Dis       Date:  2008-05-20       Impact factor: 4.982

Review 8.  [Diagnostics of Wilson's disease].

Authors:  W Hermann; D Huster
Journal:  Nervenarzt       Date:  2018-02       Impact factor: 1.214

9.  Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease.

Authors:  Mario Piga; Alessandra Murru; Loredana Satta; Alessandra Serra; Alessandro Sias; Gianluigi Loi; Francesco Marrosu; Luigi Demelia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-08       Impact factor: 9.236

10.  Neurochemical and behavioral characteristics of toxic milk mice: an animal model of Wilson's disease.

Authors:  Adam Przybyłkowski; Grażyna Gromadzka; Adriana Wawer; Ewa Bulska; Katarzyna Jabłonka-Salach; Tomasz Grygorowicz; Anna Schnejder-Pachołek; Andrzej Członkowski
Journal:  Neurochem Res       Date:  2013-07-23       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.